Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
- BRAF AGK-BRAF
- Associated Disease
- melanoma
- Source Database
- CIViC Evidence
- Description
- BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/723
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/285
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Melanoma
- Evidence Direction
- Supports
- Drug
- Sorafenib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23890088
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Sorafenib | Sensitivity | true |